Acute coronary syndromes in patients with renal disease: What are the issues?

Current Cardiology Reports

Volumn 8, Issue 4, 2006, Pages 296-300

  Panetta, Carmelo J ^b   Herzog, Charles A ^b   Henry, Timothy D ^a  

^a MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IODIXANOL; IOHEXOL; LIPID; LOW MOLECULAR WEIGHT HEPARIN; NICOTINIC ACID; RAPAMYCIN; THROMBIN INHIBITOR; TIROFIBAN;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; BLEEDING; CHRONIC KIDNEY DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DRUG CLEARANCE; DRUG ELUTING STENT; HEMODIALYSIS; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIA; KIDNEY FAILURE; LIVER DYSFUNCTION; MEDICAL RESEARCH; META ANALYSIS; MORTALITY; MYOSITIS; PERCUTANEOUS CORONARY INTERVENTION; PERITONEAL DIALYSIS; REVIEW; SYSTEMATIC REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACUTE DISEASE; CORONARY DISEASE; HUMANS; KIDNEY DISEASES; MYOCARDIAL REVASCULARIZATION; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; SYNDROME; THROMBOLYTIC THERAPY;

EID: 33745894921     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-006-0062-6     Document Type: Review

References (53)

1. Kidney disease research updates. http://kidney.niddk.nih.gov/about/Research_Updates/ KidneyDiseaseFall05/1.htm
2. Jaar BG, Coresh J, Plantinga LC, et al.: Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease. Ann Intern Med 2005, 143:174-183.
3. Lindner A, Charra B, Sherrard DJ, Scribner BH: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974, 290:697-701.
4. USRDS, Morbidity and Mortality. http://www.usrds.org/2005/pdf/06_morb_and_mort_05.pdf
5. Go AS, Chertow GM, Fan D, et al.: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305.
6. Brugts JJ, Knetsch AM, Mattace-Raso FU, et al.: Renal function and risk of myocardial infarction in an elderly population: the Rotterdam Study. Arch Intern Med 2005, 165:2659-2665.
7. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998, 339:799-805.
8. Gibson CM, Dumaine RL, Gelfand EV, et al.: Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. Eur Heart J 2004, 25:1998-2005.
9. Kirtane AJ, Leder DM, Waikar SS, et al.: Serum blood urea nitrogen as an independent marker of subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced glomerular filtration rates. J Am Coll Cardiol 2005, 45:1781-1786.
10. Dumaine R, Collet JP, Tanguy ML, et al.: Prognostic significance of renal insufficiency in patients presenting with acute coronary syndrome (the Prospective Multicenter SYCOMORE study). Am J Cardiol 2004, 94:1543-1547.
11. Shlipak MG, Heidenreich PA, Noguchi H, et al.: Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 2002, 137:555-562.
12. Wright RS, Reeder GS, Herzog CA, et al.: Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med 2002, 137:563-570.
13. Sadeghi HM, Stone GW, Grines CL, et al.: Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation 2003, 108:2769-2775.
14. Best PJ, Lennon R, Ting HH, et al.: The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002, 39:1113-1119.
15. Asinger RW, Henry TD, Herzog CA, et al.: Clinical outcomes of PTCA in chronic renal failure: a case-control study for comorbid features and evaluation of dialysis dependence. J Invasive Cardiol 2001, 13:21-28.
16. Berger PB, Best PJ, Topol EJ, et al.: The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. Am Heart J 2005, 149:869-875.
17. Rihal CS, Textor SC, Grill DE, et al.: Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002, 105:2259-2264.
18. Freeman RV, Mehta RH, Al Badr W, et al.: Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol 2003, 41:718-724.
19. de Lusignan S, Chan T, Stevens P, et al.: Identifying patients with chronic kidney disease from general practice computer records. Fam Pract 2005, 22:234-241.
20. Bolton K, Culleton B, Harvey KS, et al.: Part 4: Clinical practice guidelines for chronic kidney disease. Evaluation, classification, stratification. Am J Kidney Dis 2002, 39:S46-S75.
21. Manske CL, Thomas W, Wang Y, Wilson RF: Screening diabetic transplant candidates for coronary artery disease: identification of a low risk subgroup. Kidney Int 1993, 44:617-621.
22. Hergesell O, Zeier M: Underdiagnosis of diabetes mellitus in chronic dialysis patients on the renal transplant waiting list. Transplant Proc 2003, 35:1287-1289.
23. Creager MA, Luscher TF, Cosentino F, et al.: Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003, 108:1527-1532.
24. Stack AG, Bloembergen WE: Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study. J Am Soc Nephrol 2001, 12:1516-1523.
25. Nathan DM, Cleary PA, Backlund JY, et al.: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653.
26. Grundy SM, Cleeman JI, Merz CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
27. O'Neal D, Lee P, Murphy B, Best J. Low-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysis. Am J Kidney Dis 1996, 27:84-91.
28. Vaitkus, PT. Current status of prevention, diagnosis, and management of coronary artery disease in patients with kidney failure. Am Heart J 2000, 139:1000-1008.
29. Corsini, A: The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk. Cardiovasc Drugs Ther 2003, 17:265-285.
30. Wanner C, Krane V, Marz W, et al.: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238-248.
31. Abbas NA, John RI, Webb MC, et al.: Cardiac troponins and renal function in nondialysis patients with chronic kidney disease. Clin Chem 2005, 51:2059-2066.
32. K/DOQI Workgroup: K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005, 45:S1-S153.
33. Khan NA, Hemmelgarn BR, Tonelli M, et al.: Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: a meta-analysis. Circulation 2005, 112:3088-3096.
34. Gruberg L, Fuchs S, Waksman R, et al.: Prognostic value of cardiac troponin I elevation after percutaneous coronary intervention in patients with chronic renal insufficiency: a 12-month outcome analysis. Catheter Cardiovasc Interv 2002, 55:174-179.
35. Berger AK, Duval S, Krumholz HM: Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 2003, 42:201-208.
36. Lewis EJ, Hunsicker LC, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329:1456-1462.
37. Mann JF, Gerstein HC, Pogue J, et al.: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001, 134:629-636.
38. Verma S, Strauss M: Angiotensin receptor blockers and myocardial infarction. BMJ 2004, 329:1248-1249.
39. Grand'Maison A, Charest AF, Geerts WH. Anticoagulant use in patients with chronic renal impairment. Am J Cardiovasc Drugs 2005, 5:291-305.
40. Farooq V, Hegarty J, Chandrasekar T, et al.: Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease. Am J Kidney Dis 2004, 43:531-537.
41. Green B, Greenwood M, Saltissi D, et al.: Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes. Br J Clin Pharmacol 2005, 59:281-290.
42. Collet JP, Montalescot G, Agnelli G, et al.: Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events. Eur Heart J 2005, 26:2285-2293.
43. Chew DP, Bhatt DL, Kimball W, et al.: Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. Am J Cardiol 2003, 92:919-923.
44. Chew DP, Lincoff AM, Gurm H, et al.: Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). Am J Cardiol 2005, 95:581-585.
45. Henry TD, Schweizer M, MacDonald H, et al.: Use of bivalirudin in patients with severe renal dysfunction [abstract]. Catheter Cardiovasc Interv 2004, 62:133.
46. Keough-Ryan TM, Kiberd BA, Dipchand CS, et al.: Outcomes of acute coronary syndrome in a large Canadian cohort: impact of chronic renal insufficiency, cardiac interventions, and anemia. Am J Kidney Dis 2005, 46:845-855.
47. McCullough PA, Sandberg KR: Epidemiology of contrast-induced nephropathy. Rev Cardiovasc Med 2003, 4:S3-S9.
48. Tadros GM, Malik JA, Manske CL, et al.: Iso-osmolar radio contrast iodixanol in patients with chronic kidney disease. J Invasive Cardiol 2005, 17:211-215.
49. Aspelin P, Aubry P, Fransson SG, et al.: Nephrotoxicity effects in high-risk patients undergoing angioplasty. N Engl J Med 2003, 348:491-499.
50. Manske CL, Wang Y, Rector T, et al.: Coronary revascularisation in insulin-dependent diabetic patients with chronic renal failure. Lancet 1992, 340:998-1002.
51. Herzog CA, Ma JZ, Collins AJ: Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes. Circulation 2002, 106:2207-2211.
52. Azar RR, Prpic R, Ho KK, et al.: Impact of end-stage renal disease on clinical and angiographic outcomes after coronary stenting. Am J Cardiol 2000, 86:485-489.
53. Lemos PA, Arampatzis CA, Hoye A, et al.: Impact of baseline renal function on mortality after percutaneous coronary intervention with sirolimus-eluting stents or bare metal stents. Am J Cardiol 2005, 95:167-172.